This real-world study assessed the effectiveness of first-line pembrolizumab monotherapy in patients with metastatic non-oncogene-addicted NSCLC and PD-L1 TPS ≥ 50%, comparing those aged ≥70 years to younger patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.